IBA's Integrated Care Model Accelerates Earnings Power Amid Margin Trade-Off

The financial results for 2025 provide the hard numbers confirming IBA's strategic pivot. The company delivered record-high revenue of €620 million, a robust 24% year-over-year increase. This growth was powered by strong execution, particularly in the Clinical segment, where net sales surged 44% due to effective backlog conversion. The numbers show a company successfully scaling its integrated medical solutions model, evidenced by a new all-time high backlog of €1.6 billion.

Yet the path to this new model involves a clear trade-off. While profitability expanded, it came at the cost of gross margin. The company's gross margin decreased to 32.2% from 33.7% in 2024. Management attributes this pressure to a less favorable equipment profitability mix, including legacy low-margin projects within Proton Therapy. This is the structural friction of the transition: shifting from high-margin, capital-intensive equipment sales toward a higher-volume, service-oriented clinical business.

The bottom line, however, tells a story of accelerating earnings power. Adjusted EBIT jumped 58% to €27.4 million, well above guidance. A key driver was the strong positive contribution from Proton Therapy, which delivered €10 million in Adjusted EBIT. This segment's performance, alongside controlled operating expenses at 28% of sales, demonstrates that the new model is not just growing but becoming more profitable on an earnings basis.

In essence, the 2025 results frame the strategic shift. They confirm the growth engine is firing, with clinical services driving top-line expansion. The margin compression is a known cost of this transition, but the significant surge in earnings power suggests the company is navigating it successfully. The foundation is set for a business that trades some equipment margin for greater volume, recurring revenue, and a more resilient integrated care offering.

The Strategic Pivot: From Equipment to Integrated Solutions

The 2025 results are a milestone, but the real work of the strategic pivot is being executed through a series of deliberate initiatives. IBA is systematically building an integrated medical solutions platform, moving beyond its historical role as an equipment supplier. This shift is not a single project but a coordinated portfolio of moves designed to diversify revenue, secure future growth, and fortify the balance sheet.

A cornerstone of this expansion is the acquisition of ORA, a global leader in radiochemistry. This move directly addresses the need for a more diversified clinical portfolio. By integrating ORA's capabilities, IBA gains a critical foothold in Nuclear Medicine, a high-growth therapeutic area. This acquisition is a strategic hedge against the cyclical nature of proton therapy equipment sales and creates a more balanced revenue stream, aligning with the integrated care model.

Parallel to this commercial expansion is a major push into next-generation radiopharmaceuticals. The company's PanTera subsidiary achieved a key 2025 milestone with the start of construction on its commercial-scale 225Ac production facility. This positions IBA at the forefront of targeted alpha therapy, a promising frontier in cancer treatment. The investment signals a long-term commitment to becoming a vertical player in the radiopharmaceutical value chain, from production to clinical delivery.

Financially, the company is ensuring it has the runway to execute. The recent €125 million bank refinancing provides a stronger balance sheet and enhanced financial flexibility. This capital cushion is crucial for funding strategic investments like the PanTera facility and potential future acquisitions, while also supporting the higher working capital needs of a service-oriented business model.

Finally, the transition is being enabled by a stabilization in the underlying equipment market. The company's two-year rolling equipment book-to-bill ratio has settled at 1.0x. This equilibrium suggests the volatile, project-driven equipment cycle is moderating. For IBA, this provides the operational stability needed to shift focus from selling capital equipment toward securing long-term service contracts and managing integrated clinical programs.

Together, these initiatives form a coherent strategy. The ORA acquisition diversifies the clinical offering, the PanTera facility secures a future growth platform, the refinancing provides the capital, and the stabilized equipment market offers a foundation. The pivot is now a multi-pronged reality, building a business that leverages integrated solutions to drive sustainable growth.

Financial Impact and Valuation Trade-offs

The strategic pivot is now a financial reality, and its impact is clear in the forward-looking metrics. The company's ability to generate robust earnings growth on a lower-margin base is the central story. The 58% year-over-year increase in Adjusted EBIT to €27.4 million was achieved even as the gross margin contracted to 32.2%. This disconnect signals a fundamental shift in the profit engine: the company is prioritizing volume and integrated service delivery over the high margins historically associated with capital equipment sales.

This trade-off is managed through disciplined cost control. The company's ability to keep Group Operating Expenses under control at 28% of total sales is a critical lever. It demonstrates operational discipline that allows profitability to expand even as the underlying mix of business changes. This control is essential for maintaining a healthy bottom line during the transition, where the higher volume of clinical services may initially carry lower per-unit margins than legacy equipment projects.

For investors, the valuation calculus hinges on this tension. On one side is a powerful growth narrative: a new all-time high backlog of €1.6 billion provides significant visibility, and management has set a Group Adjusted EBIT target of at least €32 million for 2026. This points to continued earnings acceleration. On the other side is the persistent risk of margin pressure from the changing business mix, particularly from legacy low-margin projects within Proton Therapy equipment.

The core thesis, therefore, is a margin trade-off. The market is being asked to value a company that is sacrificing some of its historical equipment profitability for a more diversified, volume-driven, and recurring revenue stream. The high backlog and disciplined cost management provide a path to higher earnings, but the margin compression is not a temporary blip-it is a structural feature of the new model. The valuation will ultimately reflect how quickly the company can scale its higher-margin clinical services and radiopharmaceuticals to offset the lower-margin equipment component, all while maintaining its strong operating expense discipline.

Catalysts, Risks, and What to Watch

The strategic pivot is now in motion, but its success will be judged by a few critical watchpoints in the coming quarters. The primary catalyst is the conversion of the record €1.6 billion backlog into revenue. This backlog, with its nearly equal split between equipment and services, provides significant visibility. The pace of this conversion, and more importantly, the mix of what gets delivered, will confirm whether the company is successfully shifting toward its integrated model. Strong execution here is the engine for the promised earnings growth.

A key risk that could cap margin recovery is the persistence of low-margin legacy projects within the Proton Therapy equipment portfolio. Management explicitly cited this as a driver of the gross margin compression to 32.2% in 2025. If these lower-margin projects continue to dominate the equipment delivery mix in 2026, they will weigh on profitability even as clinical services ramp up. The margin trade-off is structural, and its resolution depends on the company's ability to steer the backlog toward higher-value integrated solutions.

The next major data point is the Q3 2026 business update, scheduled for November. Investors should monitor two things: the reported backlog conversion rate and any commentary on the equipment profitability mix. A shift toward service and clinical delivery would be a positive signal, while a continued heavy weighting of legacy equipment projects would validate the margin pressure risk. This update will provide the clearest near-term view of the pivot's trajectory.

In the meantime, the company's disciplined cost control remains a critical stabilizer. The ability to keep operating expenses under control at 28% of sales, as achieved in 2025, is a key lever for maintaining earnings power during the transition. Any deviation from this discipline would compound the margin pressures from the business mix.

The bottom line is that the path forward is now defined by these specific metrics. The high backlog is a promise, not a guarantee. The coming quarters will show whether IBA can convert that promise into profitable, integrated care delivery, or if the legacy equipment drag proves more persistent than anticipated.